Liquid biopsy : new challenges in the era of immunotherapy and precision oncology / edited by Antonio Russo, Ettore Capoluongo, Antonio Galvano, Antonio Giordano.

Format:

Book

Contributor:

Russo, Antonio, editor.

Capoluongo, Ettore, editor.

Galvano, Antonio, editor.

Giordano, Antonio, MD, editor.

Language:

English

Subjects (All):

Biopsy.

Cancer--Diagnosis.

Cancer.

Cancer--Immunotherapy.

Liquid Biopsy.

Precision Medicine.

Translational Research, Biomedical.

Immunotherapy.

Medical Subjects:

Liquid Biopsy.

Precision Medicine.

Translational Research, Biomedical.

Immunotherapy.

Physical Description:

1 online resource (252 pages)

Place of Publication:

London : Academic Press, [2023]

Summary:

Liquid Biopsy: New Challenges in the era of Immunotherapy and Precision Oncology aims to describe links between cancer, precision oncology, and liquid biopsy, focusing on their participation to immunotherapy management. The book provides updated information on the main applications of liquid biopsy and immunotherapy as well as interesting aspects useful for planning basic and translational research activities. It helps readers understand the central aspects of precision medicine in oncology, including the use of new generation technologies for translational and diagnostic settings and the main clinical trials in this area that may be useful during their research.

Contents:

Front Cover

Liquid Biopsy

Copyright Page

Contents

List of contributors

Preface

1 What is precision medicine in oncology?

1.1 Introduction: what does precision medicine mean?

1.2 The role of biomarkers in precision medicine

1.3 Classification of biomarkers

1.4 The rationale for the definition of tumor mutational burden

1.5 Collecting samples for mutational analysis: tissue or liquid biopsy?

1.6 Pragmatical aspects of precision medicine: how to build it?

1.7 Precision medicine and clinical trials: is there something different?

1.8 Precision medicine in oncology: what is its "area-of-application"?

1.9 Pharmacogenomics and precision medicine

1.10 Determination of programmed death-ligand 1 expression in non-small cell lung carcinoma in order to choose patients eli...

1.11 Through the concept of synthetic lethality: poly ADP-ribose polymerases-inhibitors and precision medicine

1.12 Colorectal cancer e microsatellite instability

1.13 Conclusions

Conflict of interest statement

References

2 Liquid biopsy: a right tool in a right context?

Subchapter 2.1 Liquid biopsy in NSCLC

Learning objectives

2.1.1 Expert opinion

2.1.2 Key points

2.1.3 Summary of clinical recommendations

Acknowledgments

Further reading

Subchapter 2.2 The role of mutated ctDNA in nonmalignant lesions: challenging aspects in liquid biopsy implementation

2.2.1 Expert opinion

2.2.2 Key points

3 Liquid biopsy: new challenges in the era of immunotherapy and precision oncology NGS and the other faces of molecular biology

3.1 Tissue or liquid biopsy?

3.2 Next-generation sequencing for identification of gene alterations in liquid biopsy.

3.3 Liquid biopsy in monitoring response to therapy

3.4 Expert opinion

3.5 Key points

3.6 Hints for deeper insight

4 Current clinically validated applications of liquid biopsy

4.1 Circulating tumor DNA in advanced non-small cell lung cancer

4.1.1 Treatment-naïve advanced non-small cell lung cancer patients

4.1.2 Advanced non-small cell lung cancer patients progressing during tyrosine kinase inhibitors

4.2 Emerging clinical applications of liquid biopsy

4.2.1 Colorectal cancer

4.2.2 Breast cancer

4.2.3 Melanoma

4.3 Liquid biopsy application in clinical research

4.3.1 Monitoring of treatment response in lung cancer

4.3.2 Monitoring of treatment response in colorectal cancer

4.4 Key points

5 Liquid biopsy and immunotherapy: is all that glitter gold?

5.1 Background: the need for predictive biomarkers for patient selection

5.1.1 Circulating tumor cells, cell-free DNA, and exosomes

5.1.2 Circulating tumor cells

5.1.3 Cell-free DNA and circulating tumor DNA

5.1.4 Exosomes

5.1.5 T-lymphocytes (the T-cell receptor) and cytokines

5.1.6 The soluble form of immune-checkpoints and other circulating proteins

Abbreviations

Key points

Expert opinion

6 Which technology performs better? From sample volume to extraction and molecular profiling

Subchapter 6.1 Molecular profiling

6.1.1 Expert opinion

6.1.2 Key points

Subchapter 6.2 Biological fluid withdrawal: how much sample volume is enough?

6.2.1 Introduction

6.2.2 Other body fluids used in liquid biopsy-based assays

6.2.3 Key points

Further reading.

Subchapter 6.3 Methods for cf/ct DNA isolation

6.3.1 Key points

Subchapter 6.4 CTC and exosome: from the enrichment to the characterization

6.4.1 Introduction

6.4.2 Exosome enrichment

6.4.3 Exosomes characterization

6.4.3.1 Role of exosomes in immunotherapy

6.4.4 Circulating tumor cells enrichment methods

6.4.4.1 Role of circulating tumor cells in immunotherapy

6.4.5 Key points

Subchapter 6.5 Circulating RNAs (miRNA, lncRNA, etc): from the enrichment to the characterization

6.5.1 Introduction

6.5.2 Housekeeping RNAs

6.5.3 Regulatory ncRNAs

6.5.4 Key points

6.5.5 Expert opinion

Subchapter 6.6 Cell-free/circulating tumor DNA profiling: from next-generation sequencing-based to digital polymerase chain...

6.6.1 Introduction

6.6.2 Targeted next-generation sequencing methods

6.6.3 Untargeted next-generation sequencing methods

6.6.4 Droplet digital polymerase chain reaction methods

6.6.5 Key points

6.6.6 Expert opinion

Subchapter 6.7 Standardization and quality assurance in liquid biopsy testing

6.7.1 Introduction

6.7.2 Cell-free DNA in liquid biopsy: preanalytical limitations

6.7.3 The preanalytical phase of circulating tumor cells analysis

6.7.4 The preanalytical phase of exosomes analysis

6.7.4.1 Sample collection, storage, and processing

6.7.4.2 Exosomes isolation

6.7.4.2.1 Ultracentrifugation-based isolation techniques

6.7.4.2.2 Ultrafiltration and size exclusion chromatography

6.7.4.2.3 Polymer precipitation

6.7.4.2.4 Immunoaffinity methods.

6.7.4.2.5 Microfluidics-based methods

6.7.5 Standardization initiatives and ISO/CEN/external quality assessment development in liquid biopsy

6.7.6 Key points

6.7.7 Expert opinion

7 Early detection screening: myth or reality?

8 Molecular tumor board

9 Future perspectives

Glossary

Index

Back Cover.

Notes:

Includes bibliographical references and index.

Description based on print version record.

Other Format:

Print version: Russo, Antonio Liquid Biopsy

ISBN:

9780128227114

0128227117